Jacky Luiten

140 | Chapter 9 57. Rauch GM, Hobbs BP, Kuerer HM, Scoggins ME, Benveniste AP, Park YM, et al. Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence. Ann Surg Oncol. 2016;23(2):482 ‐ 489. 58. Evans A, Clements K, Maxwell A, Bishop H, Hanby A, Lawrence G, et al. Lesion size is a major determinant of the mammographic features of ductal carcinoma in situ: findings from the Sloane project. Clin Radiol. 2010;65(3):181 ‐ 184. 59. Tang X, Yamashita T, Hara M, Kumaki N, Tokuda Y, Masuda S. Histopathological characteristics of breast ductal carcinoma in situ and association with imaging findings. Breast Cancer. 2016;23(3):491 ‐ 498. 60. Neal L, Sandhu NP, Hieken TJ, Glazebrook KN, Mac Bride MB, Dilaveri CA, et al. Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy. Mayo Clin Proc. 2014;89(4):536 ‐ 547. 61. Gao Y, Albert M, Young Lin LL, Lewin AA, Babb JS, Heller SL, et al. What Happens after a Diagnosis of High ‐ Risk Breast Lesion at Stereotactic Vacuum ‐ assisted Biopsy? An Observational Study of Postdiagnosis Management and Imaging Adherence. Radiology. 2018;287(2):423 ‐ 431. 62. Rageth CJ, O'Flynn EA, Comstock C, Kurtz C, Kubik R, Madjar H, et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat. 2016;159(2):203 ‐ 213. 63. Rageth CJ, O'Flynn EAM, Pinker K, Kubik ‐ Huch RA, Mundinger A, Decker T, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat. 2019;174(2):279 ‐ 296. 64. Pieri A, Hemming D, Westgarth J, Lunt L. Vacuum ‐ assisted biopsy is a viable alternative to surgical biopsy in the investigation of breast lesions of uncertain malignant potential. Surgeon. 2017;15(2):59 ‐ 64. 65. Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low ‐ risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797. 66. Van de Vijver MJ, Peterse H. The diagnosis and management of pre ‐ invasive breast disease: pathological diagnosis ‐‐ problems with existing classifications. Breast Cancer Res. 2003;5(5):269. 67. Pinder SE, Ellis IO. The diagnosis and management of pre ‐ invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) ‐‐ current definitions and classification. Breast Cancer Res. 2003;5(5):254 ‐ 257. 68. van Dooijeweert C, van Diest PJ, Willems SM, Kuijpers C, Overbeek LIH, Deckers IAG. Significant inter ‐ and intra ‐ laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Res Treat. 2019;174(2):479 ‐ 488. 69. Farabegoli F, Champeme MH, Bieche I, Santini D, Ceccarelli C, Derenzini M, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol. 2002;196(3):280 ‐ 286. 70. Lopez ‐ Garcia MA, Geyer FC, Lacroix ‐ Triki M, Marchio C, Reis ‐ Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57(2):171 ‐ 192. 71. Rainey L, van der Waal D, Jervaeus A, Wengstrom Y, Evans DG, Donnelly LS, et al. Are we ready for the challenge of implementing risk ‐ based breast cancer screening and primary prevention? Breast (Edinburgh, Scotland). 2018;39:24 ‐ 32. 72. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart ‐ Gebhart M, et al. Tailoring therapies ‐‐ improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533 ‐ 1546. 73. Li H, Whitney J, Bera K, Gilmore H, Thorat MA, Badve S, et al. Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings. Breast Cancer Res. 2019;21(1):114. 74. Rainey L, van der Waal D, Wengstrom Y, Jervaeus A, Broeders MJM. Women's perceptions of the adoption of personalised risk ‐ based breast cancer screening and primary prevention: a systematic review. Acta Oncol. 2018;57(10):1275 ‐ 1283.